Biotech News

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

Emergent BioSolutions (EBS)investors.emergentbiosolutions.com2026-05-30 02:11 ESTCompany update

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Emergent BioSolutions

Emergent BioSolutions is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

EBSEmergent BioSolutions2026-05-20 08:04:13 EST

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBSEmergent BioSolutions2026-05-18 09:03:05 EST

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

EBSEmergent BioSolutions2026-05-06 10:58:41 EST

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

EBSEmergent BioSolutions2026-05-06 10:58:40 EST

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Stock data

Close: 9.12 USD
Market cap: 470.56M USD
Exchange: NYSE
Sector: Biotechnology
Location: United States